Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBOW: Ramucirumab + Paclitaxel in Gastric Cancer
NCT01170663Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2010
- Primary completion
- Jul 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Eli Lilly and Company. Started Dec 2010; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01170663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01170663.